Hola,
¿eres nuevo aquí?

Regístrate gratis y conecta tu empresa con financiación pública, partners y proyectos.

Tengo cuenta

Regístrate

Ver video

EUC²LID

Financiado

European Lead Factory

The European Lead Factory concept proposed by the EUC2LID Consortium relates to the discovery of novel small molecule candidates to serve as starting points for subsequent optimization to either drug candidates or high-quality pha... ver más

31/05/2018

BAYER AKTIENGESELL...

197M€

Presupuesto del proyecto: 197M€

Líder del proyecto

BAYER AKTIENGESELLSCHAFT No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Ver 30 Participantes

Financiación concedida El organismo FP6 notifico la concesión del proyecto el día 2018-05-31 No tenemos la información de la convocatoria

0% 100%

30 Participantes

BAYER AKTIENGESELLSCHAFT

Lider

Leiden University Medical Ce...

N.D. | Participante

ULEI

N.D. | Participante

SANOFIAVENTIS DEUTSCHLAND GM...

N.D. | Participante

Conecta tu I+D

¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video

Proyectos interesantes

SAF2012-33481 EXPANDIENDO EL ESPACIO FARMACOLOGICO: NUEVAS HERRAMIENTAS PA... 117K€ Cerrado

BIO2008-02329 DESARROLLO DE NUEVOS ABORDAJES BASADOS EN LA ESTRUCTURA PARA... 85K€ Cerrado

SAF2014-53977-R HERRAMIENTAS DE RMN PARA EL DESARROLLO DE UNA PLATAFORMA PAR... Cerrado

UniSens Universal GPCR Activity Sensor for Next Generation Drug Disc... 3M€ Cerrado

PTQ2021-011961 Development of a novel drug screening platform to identify s... 115K€ Cerrado

PID2021-127693OB-I00 APROXIMACIONES BASADAS EN ESTRUCTURA PARA NUEVAS MODALIDADES... 312K€ Cerrado

Duración del proyecto: 64 meses Fecha Inicio: 2013-01-01
Fecha Fin: 2018-05-31

Líder del proyecto

BAYER AKTIENGESELLSCHAFT No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Presupuesto del proyecto 197M€

Descripción del proyecto The European Lead Factory concept proposed by the EUC2LID Consortium relates to the discovery of novel small molecule candidates to serve as starting points for subsequent optimization to either drug candidates or high-quality pharmacological tools for the experimental validation of targets. The concept intends to bridge academic and applied research interests. The European Lead Factory will provide an industry-like small molecule discovery platform to public investigators. It builds on a unique, comprehensive, high-quality compound collection contributed by EFPIA Pparticipants, i.e. the Pharma Consortium Compound Collection totaling over about 300.000 compounds. Screening of these previously safeguarded corporate compound libraries against competitor’s targets and targets from public sources may result in otherwise inaccessible valuable lead structures that could ultimately result in the development of novel treatment options for patients. Academic Participantsa or other eligible bodies (and Contributing Third Parties) will be invited to submit proposals for screening of innovative targets and to suggest the design of new and diverse chemical libraries utilizing novel concepts and strategies. The latter will fuel the generation of a Public Compound Collection that will combine with the Pharma ConsortiumEFPIA Compound Collection to generate the Joint European Compound CollectionLibrary. These public sector contributions will not only provide a constant flow of innovation, but also generate opportunities for future partnerships amongst public Public Participants and private contributors EFPIA Participants on scientific and commercial grounds. EUC2LID’s overarching goal is value creation by screening the Joint European Compound Collection Library against in pPublic and private EFPIA Ttarget Programmes. Based on the successful delivery on its objectives during the IMI funding period, the generation of the high quality Public Compound Collection provides a tangible asset allowing the transition of the European Lead Factory into a novel sustainable business model, facilitating future public-private alliances based on pre-competitive, community-based efforts in early drug research.

Conecta tu I+D

Entra hoy

¿Olvidé mi contraseña?

Financiación

Empresas

CTIs/Universidades

Proyectos

Investigadores